Other SGLT-2s in Development
The recent approval of Invokana is exciting, opening the door to a new class of medications that can help people to manage type 2 diabetes, but it was not exactly the only drug on that long road to approval. Take a look at other potential medications that are in various stages of trials and approvals that may join this newest class of oral medications.
Astellas Pharma – Ipragliflozin
- This drug has been filed for marketing approval in Japan and is in the process of completing phase III trials.
- Trials have shown its potential to significantly lower glycated hemoglobin levels (HbA1c) over time as compared to placebo.
Bi/Lilly – Empagliflozin
- This drug is in Phase III of clinical trial process involving over 14,500 patients. There will be a total of 12 clinical trials performed throughout several countries.
- It is said that the companies will present results of the studies at some point in 2013 or 2014.
Chugai (Roche) – Tofogliflozin Hydrate
- According to Chugai Pharma, as of November 2010, this drug is in Phase III of clinical trials.
Lexicon – LX4211
- This drug inhibits both SGLT1 and SGLT2, making it the first of its kind to be introduced in clinical development for diabetes.
- LX4211 will begin Phase III clinical studies in the middle of 2013.
Taisho Pharma – luseogliflozin
- This drug is currently in Phase III of clinical trials.
Bristol-Myers Squibb – Farxiga
- This is a once- daily oral treatment specifically geared toward type 2 diabetes, to be used in conjunction with exercise and a proper diet. This treatment is currently in clinical trials.
Reviewed by James A. Bennett 04/14.
- • Astellas. AVEO and Astellas announce postive findings from TIVO-1 superiority study of tivozanib in first line advanced RCC., http://www.astellas.com/en/corporate/news/pdf/121003_Eg_1.pdf. (PDF) (Accessed 4/11/13.)
- • Lexicon Pharmaceuticals. LX4211, http://www.lexgen.com/pipeline/lx4211.html. (Accessed 4/11/13.)
- • Chugai Pharma USA. Annual report, 2011. http://www.chugai-pharm.co.jp/hc/ss/downloads/eAR2011_12_09.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3DeAR2011_12_09.pdf&blobwhere=1259656736395&ssbinary=true. (PDF) (Accessed 4/11/13.)
- • Theheart.org. FDA approves new diabetes drug, canagliflozin, despite CV concerns, http://www.theheart.org/article/1523789.do. (Accessed 4/11/13.)
- • Drug Discovery & Development Magazine. Lilly, BI submit empagliflozin to FDA, http://www.dddmag.com/news/2013/03/lilly-bi-submit-empagliflozin-fda. (Accessed 4/11/13.)
Macaroni, Tomato, and Corn Salad Low Carb, Low Fat Sloppy Joes with Salsa Enlitened's Whipped Jello Fruit Cup Zangria-Style Iced Tea Pan-Fried Catfish with Southwest Tartar Sauce Cod Fillets with Sweet Onion and Corn Relish Sweet and Sour Cauliflower Turkey Salad With Grapes Apple Crisp with Peanut Butter Chips Seven Layer Salad
I had a bad one last night. A scary low bloodsugar that reminded me just how tenuous diabetes makes my existence. I hate those. I hate the feeling that I'm anything less than a strong, capable woman. Diabetes, like a sledge hammer to the knees, has a way of hobbling the confidence I have in my health, strength and well-being. It is both frustrating and disheartening. It's 2:00 am and a good friend called from their third shift job because they needed someone. Just...